Atherosclerosis · 2026
Soluble endoglin as a biomarker of cardiovascular and metabolic disorders related to endothelial dysfunction: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Urbankova Rathouska Jana, Emadzadeh Maryam, Nemeckova Ivana, Fikrova Petra, Tripska Katarina, Mohammadi Niloufar, Jamialahmadi Tannaz, Sahebkar Amirhossein, Nachtigal Petr
Аннотация
BACKGROUND AND AIMS: Soluble endoglin (sENG) has been discussed as a biomarker of endothelial dysfunction, associated with cardiovascular and metabolic disorders. A critical evaluation of sENG as a diagnostic tool for atherosclerotic cardiovascular diseases (ASCVD), type 1 diabetes mellitus (DM1), type 2 diabetes mellitus (DM2), hypertensive disorders, and heart failure (HF) using a meta-analysis has never been performed.
METHODS: PUBMED, SCOPUS, and Web of Science databases were searched up to August 1, 2025. Information on sENG concentrations in the group with one of the above-mentioned diagnoses and the control group was extracted and analyzed. Publication bias and quality assessment were performed using the Newcastle-Ottawa Scale (NOS) criteria.
RESULTS: 16 studies were evaluated. A total of 2113 subjects were included, comprising 1391 subjects in disease groups and 722 in the control group. sENG serum/plasma concentrations were significantly higher in disorders related to endothelial dysfunction than in controls, with a pooled mean difference of 0.92 ng/mL (95% CI: 0.50-1.34, p < 0.001). Additionally, sENG serum/plasma concentrations were significantly elevated in patients with DM1, 0.99 ng/mL (95% CI 0.45-1.54, p < 0.001), DM2, 1.98 ng/mL (95% CI 0.60-3.35, p = 0.005) and HF, 1.06 ng/mL (95% CI 0.06-2.06, p = 0.038), compared to controls.
CONCLUSIONS: This meta-analysis is the first to demonstrate that sENG serum/plasma concentrations are significantly higher in selected cardiovascular and metabolic disorders related to endothelial dysfunction. sENG might represent a novel biomarker reflecting endothelial damage only in patients with DM1, DM2, and heart failure.
METHODS: PUBMED, SCOPUS, and Web of Science databases were searched up to August 1, 2025. Information on sENG concentrations in the group with one of the above-mentioned diagnoses and the control group was extracted and analyzed. Publication bias and quality assessment were performed using the Newcastle-Ottawa Scale (NOS) criteria.
RESULTS: 16 studies were evaluated. A total of 2113 subjects were included, comprising 1391 subjects in disease groups and 722 in the control group. sENG serum/plasma concentrations were significantly higher in disorders related to endothelial dysfunction than in controls, with a pooled mean difference of 0.92 ng/mL (95% CI: 0.50-1.34, p < 0.001). Additionally, sENG serum/plasma concentrations were significantly elevated in patients with DM1, 0.99 ng/mL (95% CI 0.45-1.54, p < 0.001), DM2, 1.98 ng/mL (95% CI 0.60-3.35, p = 0.005) and HF, 1.06 ng/mL (95% CI 0.06-2.06, p = 0.038), compared to controls.
CONCLUSIONS: This meta-analysis is the first to demonstrate that sENG serum/plasma concentrations are significantly higher in selected cardiovascular and metabolic disorders related to endothelial dysfunction. sENG might represent a novel biomarker reflecting endothelial damage only in patients with DM1, DM2, and heart failure.